The metabolic disorders are the edge points for the initiation of various diseases. These disorders comprised of several diseases including diabetes,
obesity, and cardiovascular complications. Worldwide, the prevalence of these disorders is increasing day by day. The world's population is at higher threat of developing
metabolic disease, especially diabetes. Therefore, there is an impregnable necessity of searching for a newer therapeutic target to reduce the burden of these disorders.
Diabetes mellitus (DM) is marked with the dysregulated insulin secretion and resistance. The
lipid and
glucose transporters portray a pivotal role in the metabolism and transport of both of these. The excess production of
lipid and
glucose and decreased clearance of these leads to the emergence of DM. The
ATP-binding cassette transporters (ABCT) are important for the metabolism of
glucose and
lipid. Various studies suggest the key involvement of ABCT in the pathologic process of different diseases. In addition, the involvement of other pathways, including IGF signaling, P13-Akt/PKC/MAPK signaling, and
GLP-1 via regulation of ABCT, may help develop new treatment strategies to cope with
insulin resistance dysregulated
glucose metabolism, key features in DM.